Virtual Library
Start Your Search
Zhe Zhao
Author of
-
+
MA01 - Novel Systemic Treatment in NSCLC (ID 102)
- Event: WCLC 2020
- Type: Mini Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Presentations: 1
- Moderators:
- Coordinates: 1/29/2021, 11:45 - 12:45, Scientific Program Auditorium
-
+
MA01.03 - The Role of Gut Microbiome in the Efficacy of Chemotherapy in Patients With Locally Advanced and Advanced Lung Cancer (ID 1598)
11:45 - 12:45 | Presenting Author(s): Zhe Zhao
- Abstract
- Presentation
Introduction
Accumulating evidences have disclosed the important role of gut microbiome in modulating response of immunotherapy in the patients with lung cancer. However, research exploring the relationship of intestinal flora and chemotherapy is still limited. The study is to investigate the correlation between intestinal flora and chemotherapy efficacy in locally advanced and advanced lung cancer.
Methods
We analyzed baseline stool samples from lung cancer patients before chemotherapy treatment, through metagenomics of gut microbiota. The composition, diversity, function and metabolic pathway of microbial communities were compared among patients with different chemotherapy response.
Results
From September 1, 2018 to September 30, 2019, 64 consecutive lung cancer patients treated with chemotherapy were included into this study. All patients provided the stool samples. 33 of 64 patients responded to treatment (responders) and another 31 patients didn’t (non-responders). The median progression-free survival was 7 months (range, 1.5-14.5). Streptococcus_mutans (P=0.026) and Enterococcus_casseliflavus (P=0.049) were enriched in responders, while 11 bacteria including Leuconostoc_lactis (P=0.002) were enriched in non-responders. Functional analysis of metabolic pathways revealed that L-glutamate degradation VIII pathway was enriched in responders (P=0.014), and 3 pathways including C4 photosynthetic carbon assimilation cycle were enriched in non-responders (P<0.05). Patients enriched with 5 bacterial species, such as Turicibacter_sanguinis (P=0.008) had longer progression-free survival than those enriched in the 7 bacteria including Streptococcus_anginosus (P=0.013) (HR, 0.189; 95% CI, 0.092-0.387; P< 0.0001). Purine nucleobases degradation I and other 4 metabolic pathways were enriched in lung cancer patients with longer progression-free survival (P<0.05). In addition, significant associations of certain bacterial species with clinical parameters such as pathological pattern were observed by spearman correlation analysis.
Conclusion
The study indicated that specific intestinal bacteria may be associated with the clinical outcome of locally advanced and advanced lung cancer patients with chemotherapy, which need to be validated by prospective and large samples studies.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
